Research graph
References from Efficacy and safety of Xuesaitong soft capsule plus antiplatelet agents in ischemic stroke patients: a large-scale, multicenter, controlled, retrospective real-world study. Local targets link to admitted publications; unresolved targets remain external evidence.
Impact of aging and comorbidities on ischemic stroke outcomes in preclinical animal models: a translational perspective
10.1016/j.expneurol.2020.113494 · 2021 · External reference
Endovascular stroke thrombectomy for patients with large ischemic core: a review
10.1001/jamaneurol.2024.2500 · 2024 · External reference
The importance of comorbidities in ischemic stroke: impact of hypertension on the cerebral circulation
10.1177/0271678x18800589 · 2018 · External reference
Panax notoginseng saponins and acetylsalicylic acid co-delivered liposomes for targeted treatment of ischemic stroke
10.1016/j.ijpharm.2024.124782 · 2024 · External reference
Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis
10.1186/s12883-021-02341-2 · 2021 · External reference
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021
10.1016/s0140-6736(24)00757-8 · 2024 · External reference
Atherosclerosis: known and unknown
10.1111/pin.13202 · 2022 · External reference
Panax notoginseng saponins alleviates inflammation induced by microglial activation and protects against ischemic brain injury via inhibiting HIF-1alpha/PKM2/STAT3 signaling
10.1016/j.biopha.2022.113479 · 2022 · External reference
The efficacy and safety of the Xuesaitong soft capsule in the treatment of patients with ischemic stroke: systematic review and meta-analysis
10.21037/apm-22-748 · 2022 · External reference
Antithrombotic therapy for primary and secondary prevention of ischemic stroke: JACC state-of-the-art review
10.1016/j.jacc.2023.07.025 · 2023 · External reference
Balancing benefits and risks of long-term antiplatelet therapy in noncardioembolic transient ischemic attack or stroke
10.1161/strokeaha.120.031755 · 2021 · External reference
Stroke
10.1016/s0140-6736(24)00642-1 · 2024 · External reference
Contemporary management of acute ischemic stroke
10.1146/annurev-med-050823-094312 · 2025 · External reference
The efficacy and safety of ischemic stroke therapies: an umbrella review
10.3389/fphar.2022.924747 · 2022 · External reference
A narrative review of Panax notoginseng: unique saponins and their pharmacological activities
10.1016/j.jgr.2024.12.005 · 2025 · External reference
Special issue: comorbidities in stroke outcomes: novel therapeutic targets
10.1016/j.expneurol.2021.113641 · 2021 · External reference
Panax notoginseng saponins inhibits atherosclerotic plaque angiogenesis by down-regulating vascular endothelial growth factor and nicotinamide adenine dinucleotide phosphate oxidase subunit 4 expression
10.1007/s11655-014-1832-4 · 2015 · External reference
Advances in treatments for acute ischemic stroke
10.1136/bmj-2023-076161 · 2025 · External reference
Comparative analysis of compatibility influence on invigorating blood circulation for combined use of Panax Notoginseng saponins and aspirin using metabolomics approach
10.3389/fphar.2021.544002 · 2021 · External reference
Thrombolysis for acute ischaemic stroke: current status and future perspectives
10.1016/s1474-4422(22)00519-1 · 2023 · External reference
Recurrent cardiovascular and limb events in 294,428 patients with coronary or peripheral artery disease or ischemic stroke on antiplatelet monotherapy: the RESRISK cohort study
10.1016/j.atherosclerosis.2024.118589 · 2024 · External reference
Dual antiplatelet therapy: a concise review for clinicians
10.3390/life13071580 · 2023 · External reference
Combination of Panax notoginseng saponins and aspirin potentiates platelet inhibition with alleviated gastric injury via modulating arachidonic acid metabolism
10.1016/j.biopha.2020.111165 · 2021 · External reference
Acute ischaemic stroke: recent advances in reperfusion treatment
10.1093/eurheartj/ehac684 · 2023 · External reference
Bleeding from antiplatelet agents in patients with stroke and transient ischemic attack: how important is it?
10.1212/wnl.0000000000200863 · 2022 · External reference
Efficacy and safety of Panax notoginseng saponins in the treatment of adults with ischemic stroke in China: a randomized clinical trial
10.1001/jamanetworkopen.2023.17574 · 2023 · External reference
Panax notoginseng saponins promotes angiogenesis after cerebral ischemia-reperfusion injury
10.1016/j.jgr.2024.08.004 · 2024 · External reference
Anti-platelet aggregation of Panax notoginseng triol saponins by regulating GP1BA for ischemic stroke therapy
10.1186/s13020-021-00424-3 · 2021 · External reference
Protective effect of Panax Notoginseng saponins on Apolipoprotein-E-deficient atherosclerosis-prone mice
10.2174/1381612828666220128104636 · 2022 · External reference
Notoginsenoside R1 alleviates cerebral ischemia/reperfusion injury by inhibiting the TLR4/MyD88/NF-kappaB signaling pathway through microbiota-gut-brain axis
10.1016/j.phymed.2024.155530 · 2024 · External reference
The plant extract PNS mitigates atherosclerosis via promoting Nrf2-mediated inhibition of ferroptosis through reducing USP2-mediated Keap1 deubiquitination
10.1111/bph.17311 · 2024 · External reference
Xuesaitong injection (lyophilized) combined with aspirin and clopidogrel protect against focal cerebral ischemic/reperfusion injury in rats by suppressing oxidative stress and inflammation and regulating the NOX2/IL-6/STAT3 pathway
10.21037/apm-20-1681 · 2021 · External reference
